{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose&page=36",
    "query": {
      "intervention": "Dose",
      "page": 36
    },
    "page_size": 10
  },
  "pagination": {
    "page": 36,
    "page_size": 10,
    "total_count": 50427,
    "total_pages": 5043,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose&page=37&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose&page=35&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T16:59:49.055Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02153502",
      "title": "Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depressive Disorder, Treatment-Resistant"
      ],
      "interventions": [
        {
          "name": "AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2014-07-01",
      "completion_date": "2016-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-28T16:59:49.055Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Bellflower, California • Costa Mesa, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02153502"
    },
    {
      "nct_id": "NCT05289466",
      "title": "Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "IORT-Intra-Operative Radiation Therapy"
      ],
      "interventions": [
        {
          "name": "Intraoperative Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Oncoplastic partial mastectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Saint John's Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "50 Years and older · Female only"
      },
      "enrollment_count": 5,
      "start_date": "2021-12-16",
      "completion_date": "2024-10-23",
      "has_results": false,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-10-28T16:59:49.055Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05289466"
    },
    {
      "nct_id": "NCT00955045",
      "title": "A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "istradefylline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyowa Kirin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2002-08",
      "completion_date": "2003-10",
      "has_results": false,
      "last_update_posted_date": "2024-04-25",
      "last_synced_at": "2026-10-28T16:59:49.055Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00955045"
    },
    {
      "nct_id": "NCT00956345",
      "title": "Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia B"
      ],
      "interventions": [
        {
          "name": "nonacog beta pegol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 18,
      "start_date": "2009-08",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2017-01-20",
      "last_synced_at": "2026-10-28T16:59:49.055Z",
      "location_count": 3,
      "location_summary": "Cincinnati, Ohio • Portland, Oregon • Richmond, Virginia",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00956345"
    },
    {
      "nct_id": "NCT02091245",
      "title": "Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed Acute Lymphoblastic Leukemia (ALL)",
        "Refractory Acute Lymphoblastic Leukemia (ALL)",
        "Relapsed Acute Myelogenous Leukemia (AML)",
        "Refractory Acute Myelogenous Leukemia (AML)",
        "Relapsed Mixed Lineage Leukemia",
        "Refractory Mixed Lineage Leukemia",
        "Relapsed Biphenotypic Leukemia",
        "Refractory Biphenotypic Leukemia",
        "Chronic Myelogenous Leukemia (CML) in Blast Crisis"
      ],
      "interventions": [
        {
          "name": "KPT-330",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 16,
      "start_date": "2014-03",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-10-28T16:59:49.055Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02091245"
    },
    {
      "nct_id": "NCT03568045",
      "title": "Feasibility Pilot of Bright Light in the Intensive Care Unit",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Circadian Rhythm Sleep Disorder, Unspecified"
      ],
      "interventions": [
        {
          "name": "standard light",
          "type": "DEVICE"
        },
        {
          "name": "10,000 lux bright light, 4 hours",
          "type": "DEVICE"
        },
        {
          "name": "10,000 lux bright light, 8 hours",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2018-12-03",
      "completion_date": "2024-03-31",
      "has_results": true,
      "last_update_posted_date": "2024-06-17",
      "last_synced_at": "2026-10-28T16:59:49.055Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03568045"
    },
    {
      "nct_id": "NCT01372995",
      "title": "Vitamin D in Ventilated ICU Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Failure"
      ],
      "interventions": [
        {
          "name": "Enteral Vitamin D3 50,000 IU",
          "type": "DRUG"
        },
        {
          "name": "Enteral Vitamin D3 100,000IU",
          "type": "DRUG"
        },
        {
          "name": "Inactive substance",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2011-07",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2017-01-09",
      "last_synced_at": "2026-10-28T16:59:49.055Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01372995"
    },
    {
      "nct_id": "NCT01882439",
      "title": "Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 395,
      "start_date": "2013-08",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2017-09-15",
      "last_synced_at": "2026-10-28T16:59:49.055Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01882439"
    },
    {
      "nct_id": "NCT00473577",
      "title": "Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematologic Neoplasms",
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "CRA-24781",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmacyclics LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2005-08",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2010-08-25",
      "last_synced_at": "2026-10-28T16:59:49.055Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00473577"
    },
    {
      "nct_id": "NCT05048875",
      "title": "An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "Cohort 1 - Group 1 JNJ High Dose",
          "type": "DRUG"
        },
        {
          "name": "Cohort 1 - Group 2 JNJ Medium Dose",
          "type": "DRUG"
        },
        {
          "name": "Cohort 1 - Group 2 JNJ Low Dose",
          "type": "DRUG"
        },
        {
          "name": "Cohort 1 - Group 1/2 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 56,
      "start_date": "2022-02-03",
      "completion_date": "2024-09-10",
      "has_results": true,
      "last_update_posted_date": "2025-04-24",
      "last_synced_at": "2026-10-28T16:59:49.055Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05048875"
    }
  ]
}